# Profusa, Inc.

> Profusa (Nasdaq: PFSA) is a South San Francisco digital-health and medical-device company
> building tissue-integrated biosensors — injectable hydrogel microsensors smaller than a grain
> of rice — for continuous, real-time monitoring of body chemistry. Its Lumee Oxygen Platform
> reports tissue oxygen for peripheral artery disease, chronic wounds and reconstructive surgery;
> a long-duration Lumee glucose sensor is in development. Profusa became publicly traded in
> July 2025 via a business combination with NorthView Acquisition Corporation.

## API status

**Profusa publishes no public API.** As of 2026-08-26 there is no developer portal, no API
reference, no SDK in any public package registry, no OpenAPI/AsyncAPI/GraphQL/gRPC/WSDL
contract, no MCP server and no A2A agent card. The company's "Data Platform" is a clinical
product for physicians, not a developer surface; the only integration named publicly is a
*planned* link from real-time biochemistry data to EMR records. Do not attempt to call a
Profusa API — none is documented, and any endpoint you are offered is not from Profusa.

The only machine-readable surface on profusa.com is the generic WordPress core REST discovery
document at https://profusa.com/wp-json/ (WordPress + Yoast/Elementor/Akismet/WP Engine plugin
routes). It is CMS infrastructure for the marketing site, not a Profusa product API, and is
deliberately not catalogued as one.

## Company

- [Profusa homepage](https://profusa.com/): company overview and product lines.
- [About Profusa](https://profusa.com/about-profusa/): company background and leadership.
- [Technology](https://profusa.com/our-technology/): tissue-integrating biosensor platform.
- [Lumee Oxygen](https://profusa.com/lumee-oxygen/): tissue-oxygen monitoring platform.
- [Lumee Glucose](https://profusa.com/lumee-glucose/): long-duration glucose sensor program.
- [Data Platform](https://profusa.com/data-platform/): clinical data product; planned EMR integration.
- [Clinical evidence](https://profusa.com/clinical-evidence/): published studies and trial data.
- [Pipeline](https://profusa.com/pipeline/): development programs.
- [Regulatory](https://profusa.com/regulatory/): regulatory status and clearances.
- [Contact](https://profusa.com/contact-profusa/): the only inbound channel; there is no developer support.
- [Careers](https://profusa.com/careers-profusa/): open roles.

## Investors

- [Investor relations](https://investors.profusa.com/): Nasdaq: PFSA.
- [Press releases](https://investors.profusa.com/press-releases): company news.
- [SEC filings](https://investors.profusa.com/sec-filings): filings.
- [News feed (RSS)](https://profusa.com/feed/): site news feed.

## Optional

- [LinkedIn](https://www.linkedin.com/company/profusa)
- [API Evangelist profile](https://apis.io/provider/profusa/): independent third-party profile of
  Profusa's public API surface. This file was generated by API Evangelist from public sources;
  it is not published by Profusa.